Peter Hau
0000-0003-3894-5053
Publication & Citation Trends
Publications
0 total
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Cited by 0
Semantic Scholar
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma
Cited by 1
Semantic Scholar
End-of-life Challenges in Neuro-oncological Patient Care: A Survey from the Junge Neuroonkologische Arbeitsgemeinschaft
Cited by 0
Semantic Scholar
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.
Cited by 4
Semantic Scholar
440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Cited by 2
Semantic Scholar
Targeted agents in patients with progressive glioblastoma—A systematic meta‐analysis of randomized clinical trials OA
Cited by 2
Semantic Scholar
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
Cited by 2
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(283)
Brain Metastases and Treatment
(91)
Cancer Cells and Metastasis
(44)
Radiomics and Machine Learning in Medical Imaging
(44)
Cancer, Hypoxia, and Metabolism
(43)
Affiliations
Boston University
Goethe University Frankfurt
University of Bern
Regensburg University of Applied Sciences
Hudson Institute